Joseph E. Blaney
31Patents
6h-index
13Co-inventors
66Inventor score
Filing activity: Nov 21, 2003 → Jul 19, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7517531B2 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | Emerging Cross-Sectional Technologies | 13 | Active |
| US8075903B2 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4 | Emerging Cross-Sectional Technologies | 12 | Active |
| US7226602B2 | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses | Emerging Cross-Sectional Technologies | 11 | Expired |
| US8632782B2 | Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region | Emerging Cross-Sectional Technologies | 9 | Active |
| US7560118B2 | Attenuated dengue virus comprising mutations in the NS3 gene | Emerging Cross-Sectional Technologies | 7 | Active |
| USRE46042E1 | Development of dengue virus vaccine components | General | 7 | Active |
| USRE46631E1 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | General | 6 | Active |
| US8039003B2 | Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis | Emerging Cross-Sectional Technologies | 6 | Active |
| US9090873B2 | Development of dengue virus vaccine components | Emerging Cross-Sectional Technologies | 5 | Active |
| US8337860B2 | Development of dengue virus vaccine components | Emerging Cross-Sectional Technologies | 5 | Active |
| US9783787B2 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 | Emerging Cross-Sectional Technologies | 5 | Active |
| USRE46641E1 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | General | 5 | Active |
| US10058602B2 | Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus | Emerging Cross-Sectional Technologies | 3 | Active |
| USRE45016E1 | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses | General | 3 | Active |
| US8778671B2 | Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus | Emerging Cross-Sectional Technologies | 3 | Active |
| USRE45053E1 | Attenuated dengue virus comprising mutations in the NS3 gene | General | 3 | Active |
| US9707287B2 | Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein | Emerging Cross-Sectional Technologies | 2 | Active |
| US11332722B2 | Development of dengue virus vaccine components | Emerging Cross-Sectional Technologies | 0 | Active |
| US10849975B2 | Multivalent vaccines for rabies virus and filoviruses | Chemistry; Metallurgy | 0 | Active |
| US10456461B2 | Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus | Emerging Cross-Sectional Technologies | 0 | Active |
| US12203100B2 | Development of dengue virus vaccine components | Emerging Cross-Sectional Technologies | 0 | Active |
| US11318196B2 | Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein | Emerging Cross-Sectional Technologies | 0 | Active |
| US11746335B2 | Development of dengue virus vaccine components | Emerging Cross-Sectional Technologies | 0 | Active |
| US10500264B2 | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses | Emerging Cross-Sectional Technologies | 0 | Active |
| US10160957B2 | Development of dengue virus vaccine components | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.